Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392

Watchlist Manager
Beijing Wantai Biological Pharmacy Enterprise Co Ltd Logo
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Watchlist
Price: 73.95 CNY -3.08% Market Closed
Market Cap: 93.6B CNY
Have any thoughts about
Beijing Wantai Biological Pharmacy Enterprise Co Ltd?
Write Note

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Treasury Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Treasury Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Treasury Stock CAGR 3Y CAGR 5Y CAGR 10Y
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Treasury Stock
-ÂĄ129.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Treasury Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Treasury Stock
-ÂĄ399.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Beijing Wantai Biological Pharmacy Enterprise Co Ltd
Glance View

Market Cap
93.8B CNY
Industry
Biotechnology

In the bustling corridors of Beijing's biotechnology landscape, Beijing Wantai Biological Pharmacy Enterprise Co Ltd has emerged as a significant player, weaving a narrative of innovation and growth. Founded in 1991, Wantai has dedicated itself to the research, development, production, and marketing of in vitro diagnostic tests and vaccines. The company's strategic focus on infectious disease diagnostics has positioned it as a crucial contributor to public health efforts globally. With its widespread product portfolio covering respiratory diseases, sexually transmitted infections, and enteric pathogens, the firm's offerings are integral for medical professionals who rely on Wantai's reliable and precise diagnostic tools to make critical healthcare decisions. Wantai's success isn't merely confined to market presence. The company prides itself on a robust pipeline of vaccine development, targeting diseases neglected by the mainstream pharmaceutical industry. Notably, it gained significant attention during the COVID-19 pandemic for developing diagnostic tests that became pivotal in many countries' strategies to manage and track the virus. The firm's revenue streams are diversified across both domestic and international sales, bolstered by strategic partnerships and collaborations with global health organizations. By remaining at the frontier of scientific advancement and healthcare needs, Wantai thrives not just through innovation but also through its commitment to solving some of the world's most pressing health challenges.

Intrinsic Value
62.75 CNY
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Treasury Stock?
Treasury Stock
-129.4m CNY

Based on the financial report for Dec 31, 2023, Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Treasury Stock amounts to -129.4m CNY.

What is Beijing Wantai Biological Pharmacy Enterprise Co Ltd's Treasury Stock growth rate?
Treasury Stock CAGR 1Y
35%

Over the last year, the Treasury Stock growth was 35%.

Back to Top